Two Texas Pharmacies Recalled Compounded Glutathione This Month. Here's What Endotoxin Actually Means

What happened

On August 5, 2026, Victory Medical Center Pharmacy in Austin, Texas, issued a voluntary nationwide recall of three lots of its Compounded Glutathione 200 mg/mL multi-dose vials, lots 1980571, 1981940, and 1984345, all expiring August 27, 2026. The pharmacy's own testing had found elevated bacterial endotoxin levels. The product had gone out to patients in Texas, Florida, and New York, and the pharmacy reported adverse events including fever, chills, severe headache, nausea, vomiting, a racing heartbeat, blood pressure changes, and injection site reactions.

Two weeks later, on August 19, 2026, Optimal Balance Pharmacy in Houston recalled one lot of its Compounded Glutathione 200 mg/mL, 30 mL multi-dose vials, lot LG342009076, expiring October 4, 2026. Same reason: pharmacy testing found elevated bacterial endotoxin. This one had reached a wider footprint, patients in fourteen states including Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Texas, Utah, Vermont, and Washington. Reported symptoms were similar: fever, chills, severe headache, nausea, vomiting, pain, and reactions consistent with an allergic response.

Both pharmacies are 503A compounding pharmacies, meaning they compound to a specific patient's prescription rather than manufacturing at industrial scale, and both recalls are voluntary and patient-level, the most thorough tier the FDA recognizes. There's no evidence the two events share a source. They're two separate pharmacies, two separate compounding operations, and as far as either notice says, two unrelated failures that happened to surface the same problem within two weeks of each other.

What clean technique can't fix

The instinct when you hear "contaminated injectable" is to think about how it was handled, whether a vial sat open too long or a needle wasn't swapped between draws. Endotoxin doesn't work that way, and that's the part worth sitting with.

That's why both recall notices describe the same injury pathway even though the pharmacies, lots, and geography differ. Injectable endotoxin at high enough levels can trigger fever, chills, a drop in blood pressure, and in the FDA's own language for both notices, "inflammatory reactions, anaphylactic shock and death." It's a dose-and-detection problem, not a hygiene problem, which is exactly why testing for it before a batch ships is the step that matters most.

What actually caught this

Here's the detail that's easy to miss under the headline. In both cases, it wasn't a hospital, an outside lab, or a patient complaint that surfaced the problem first. It was the pharmacies' own required testing, the same testing 503A compounding pharmacies are obligated to run on sterile batches before and after they leave the door. That testing found the elevated endotoxin, and both pharmacies pulled the affected lots and notified the FDA and their patients.

That's the regulated channel doing what it's supposed to do. A licensed compounding pharmacy has to test, has to report, and has to recall, and when the system worked as designed here, it caught contamination before it reached a scale bigger than what these two notices describe. That's worth separating from the headline instinct to read "recall" as "the whole category is dangerous." Two recalls in two weeks is a real cluster and a real reason to pay attention, but it's also two instances of testing requirements doing their job, not two instances of nobody checking.

That distinction matters more once you look outside the regulated channel. Research-grade peptides sold online, including glutathione sold under a research-use label, carry no equivalent testing requirement at all. Nobody has to check those vials for endotoxin before they ship, and nobody has to recall them if they're contaminated, because there's no regulatory structure requiring either. We've written before about how only about 30% of research-peptide vendors publish a lab-verifiable Certificate of Analysis, and separately about why a purity percentage alone doesn't tell you what you actually need to know. Endotoxin testing is a further layer past both of those, and it's one more thing that a compounding pharmacy is required to run and most gray-market sellers simply aren't.

What this means for you right now

If you have glutathione from either pharmacy, check the lot number against 1980571, 1981940, or 1984345 for Victory Medical Center Pharmacy, or LG342009076 for Optimal Balance Pharmacy. If it matches, stop using it, quarantine the vial, and contact the pharmacy directly, both notices list a phone number for retrieval and refund. If you've had fever, chills, or any reaction after an injection from either source, contact your prescribing provider and consider reporting it to the FDA's MedWatch program.

If you're buying research-use glutathione or any injectable peptide through the gray market rather than a prescription, this is a good prompt to ask a vendor directly whether they test finished batches for endotoxin, not just for identity and purity, and to ask to see that specific certificate rather than taking "third-party tested" as a settled claim. It's a fair question, and a vendor with a real answer will have no trouble giving you one.

What to watch next

Neither notice has been linked to a common supplier or raw material, and nothing so far suggests these are the first two of a larger pattern rather than two separate failures. We'll follow up if the FDA connects the two events, if either pharmacy issues an expanded recall, or if a third compounding pharmacy reports the same finding.